Navigation Links
S*BIO Completes US$26 Million Equity Financing
Date:10/20/2008

currently in Phase 1 clinical trials in both Singapore and Canada.

About SB1518

Currently in Phase 1 clinical trials in the U.S., SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in certain types of hematological disorders. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of a variety of cancers and other hematological disorders.

About Bio*One Capital

Bio*One Capital is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. Investments are focused on promising and innovative global biomedical companies where Bio*One Capital can play a value adding role in bridging and supporting companies' growth strategies in Asia through their operations in Singapore. A part of the Singapore Economic Development Board, Bio*One Capital oversees a portfolio of over 50 companies in US, Europe, Singapore and Asia. For more information, please visit http://www.bio1capital.com.

About Aravis Venture

Aravis Venture, founded in 2001, is an international venture capital group focusing on private biotech and renewable energy companies with presence in Cayman, Switzerland, Singapore and Menlo Park, California. The Aravis investment team is comprised of 13 partners, investment experienced leading scientists, venture capitalists and operating executives who have been involved with the successful financing, growth and realization of more than 80 companies worldwide over the last 20 years. With the combined know how of scientific/technical expertise and management, Aravis seeks to add value to its investments by actively participating in the buildup and growth of its portfolio companies. For more information, please
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Carrington Completes $8 Million Financing
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. New Brunswick Scientific Completes Merger Transaction with Eppendorf
8. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
9. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Companys Partner Completes Trial Production of a New Antiviral Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) ... fostering and monetization of intellectual property, today announced that ... period ending June 30, 2014 on Monday, August 18, ... at 10 a.m. ET on Monday, August 18, 2014 ... led by the company,s CEO, Anthony Hayes . ...
(Date:7/24/2014)... 2014 The patent provides substantially ... test results. It also enables true sample ID ... and reporting of high profile assays such as ... rapidly growing area of biotechnology that includes DNA ... and companion diagnostics in personalized medicine. The new ...
(Date:7/23/2014)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... For the second quarter ended June ... $7.0 million, or $0.10 per share, compared to a ... for the same period in 2013. As of June ... securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University ... have succeeded in embedding nearly perfect semiconductor crystals ... of producing hybrid nanowires, very fast and multi-functional ... chip in the future. The research results will ... . , Nano-optoelectronics are considered the cornerstone of ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9A crystal wedding in the nanocosmos 2
... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the "Company") ... ended March 31, 2010 . , ... "We have recently seen a range of ... mechanism of action and provided evidence of synergies with currently approved ...
... PARIS , May 12, 2010 , ... - New Outcomes Trial to Expand Evidence ... , ... of a multinational, randomized double-blind Phase IIIb trial,PALLAS, to assess the potential clinical benefit ...
... Scientists from Zymes LLC, the University of Windsor ... of Canada presented their research at the 2010 ... 28th .  The paper entitled, " Protection of SNpc neurons by ... disease: The role of neurotrophic factors," describes a potential treatment ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 2Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 3Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 4Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 5Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 6Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 7Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 8Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 2Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 3Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 4Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 5Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 6Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 7Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 8Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 10Zymes’ Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson’s Disease 2
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... in which life arose have been maintained in our cells ... , Research published today in the Journal of Biological ... likely also in animals still perform ancient reactions thought to ... four billion years ago. , The primordial soup theory suggests ... result of the combination of metals, gases from the atmosphere ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... COLUMBIA Taking vitamin D supplements during pregnancy is not ... preterm labor/births and infections, according to results of a randomized ... (PAS) annual meeting in Vancouver, British Columbia, Canada. ... D could cause birth defects, according to Carol L. Wagner, ...
... UniversityCorpus Christi were astounded to find that seamounts, mountains that ... common ocean habitats in the world. Their findings are published ... prevalence of seamounts, which are treasure troves of marine biodiversity. ... never see a seamount, but this study shows that they ...
... of daily diet advice? If only we knew which ... new finding by a team of Cornell University researchers, dieters ... adhere to their diet. Understandably, they also report losing ... Brian Wansink, Director of the Cornell Food and Brand Lab, ...
Cached Biology News:Researchers recommend pregnant women take 4,000 IU vitamin D a day 2Scientists identify seamounts as significant, unexplored territory 2
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Biotin label transfer is fast emerging ... interaction discovery and confirmation. Until now, only ... targeted with label transfer reagents such as ... chain analog, Mts-Atf-LC-Biotin, are exciting additions to ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
Biology Products: